Emmaus Life Sciences returns to profit in Q2 FY26; revenue more than doubles to $6.3 million vs Q2 FY25

• Emmaus Life Sciences swung to net income of $1.3 million in Q2 2026 from a net loss a year earlier.
• Net revenues more than doubled to $6.3 million, up 124% year over year.
• Results included $4.8 million of revenue from an upfront fee and royalties under the NeoImmuneTech license agreement.
• Other expense climbed 81% to $2.5 million, while selling expense fell 27% to $0.5 million.
• Cash and cash equivalents totaled $2.8 million at June 30, 2026, with management citing substantial doubt about going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-351833), on August 14, 2026, and is solely responsible for the information contained therein.